AEON
AEON Biopharma, Inc. Class A · AMEX
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website aeonbiopharma.com
- Employees(FY) 8
- ISIN US00791X1000
Performance
-7.83%
1W
-77.79%
1M
-84.53%
3M
-67.52%
6M
-78.75%
YTD
-85.19%
1Y
Profile
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
Technical Analysis of AEON 2024-05-10
Overview:
In analyzing the technical indicators for AEON stock over the last 5 days, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining key metrics such as moving averages, MACD, RSI, Bollinger Bands, and OBV, we aim t...
Recent News & Updates
- 2024-05-14 04:05
AEON Biopharma Reports First Quarter 2024 Financial Results(Globenewswire)
- 2024-05-08 21:35
- 2024-05-08 20:00
AEON Biopharma Provides Update on Development Pipeline(Globenewswire)
- 2024-05-03 04:08
- 2024-05-03 03:55
Sector Update: Health Care Stocks Mixed Late Afternoon(Yahoo Finance)
- 2024-05-03 02:37
Top Midday Decliners(Yahoo Finance)
- 2024-05-02 21:05
Sector Update: Health Care Stocks Mixed Pre-Bell Friday(Yahoo Finance)
- 2024-05-02 20:31
- 2024-05-02 19:00
- 2024-03-30 10:53
- 2024-03-29 04:15
AEON Biopharma Announces Redemption of Public Warrants(Globenewswire)
- 2024-03-29 03:45
- 2024-03-19 16:30
- 2024-03-19 16:29
- 2024-03-19 04:30
- 2024-01-18 16:05
- 2024-01-18 03:05
- 2023-12-12 08:00
- 2023-12-11 19:00
- 2023-11-14 15:49
- 2023-11-12 19:15
AEON Biopharma Reports Third Quarter 2023 Financial Results(Globenewswire)
- 2023-10-19 04:05
- 2023-08-28 20:00
- 2023-08-23 20:00
- 2023-08-15 19:00
- 2023-07-23 19:00
Page 1 of 1
previousnext